Sign Up to like & get
recommendations!
1
Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s365416
Abstract: Abstract Losses of 5–10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg…
read more here.
Keywords:
insight semaglutide;
semaglutide chronic;
clinical insight;
management ... See more keywords